• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Tocilizumab alleviates cytokine storm with acute respiratory distress syndrome in severe SARS-CoV-2 infection in Taiwan.托珠单抗可缓解台湾地区严重SARS-CoV-2感染伴急性呼吸窘迫综合征的细胞因子风暴。
Intern Med J. 2021 Sep;51(9):1543-1544. doi: 10.1111/imj.15335.
2
Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.托珠单抗治疗 COVID-19 诱导的细胞因子风暴和急性呼吸窘迫综合征：来自宾夕法尼亚州西部农村一级创伤中心的病例系列。
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211019557. doi: 10.1177/23247096211019557.
3
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.托珠单抗治疗细胞因子风暴综合征的 SARS-CoV-2 患者：一项叙述性综述。
Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954.
4
A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.托珠单抗治疗 COVID-19 急性呼吸窘迫综合征的全面综述
J Clin Pharmacol. 2020 Sep;60(9):1131-1146. doi: 10.1002/jcph.1693. Epub 2020 Jul 27.
5
Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome.病例报告：卡那奴单抗治疗 COVID-19 急性呼吸窘迫综合征患者。
Front Immunol. 2020 Aug 25;11:1942. doi: 10.3389/fimmu.2020.01942. eCollection 2020.
6
Assessment of Tocilizumab (Humanized Monoclonal Antibody) for Therapeutic Efficacy and Clinical Safety in Patients with Coronavirus Disease (COVID-19).评估托珠单抗（人源化单克隆抗体）治疗新型冠状病毒肺炎（COVID-19）患者的疗效和临床安全性。
Medicina (Kaunas). 2022 Aug 10;58(8):1076. doi: 10.3390/medicina58081076.
7
Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series.白细胞介素6抑制剂托珠单抗在日本新冠病毒相关急性呼吸窘迫综合征所致细胞因子释放综合征患者中的应用：病例系列
Respir Investig. 2020 Nov;58(6):510-512. doi: 10.1016/j.resinv.2020.09.006. Epub 2020 Oct 7.
8
Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.托珠单抗治疗 COVID-19 中的“细胞因子风暴综合征”：一例报告。
Acta Med Indones. 2021 Apr;53(2):194-201.
9
Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.静脉注射托珠单抗治疗 COVID-19 相关炎症综合征的有效性和安全性：Covizumab-6 观察性队列研究。
Clin Immunol. 2021 Feb;223:108631. doi: 10.1016/j.clim.2020.108631. Epub 2020 Nov 12.
10
Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab.COVID-19 相关干燥综合征患者单剂托珠单抗治疗后即刻改善严重呼吸窘迫
Intern Med. 2021 Feb 15;60(4):639-643. doi: 10.2169/internalmedicine.6010-20. Epub 2020 Dec 29.

引用本文的文献

1
Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19).用于治疗 SARS-CoV2 感染（COVID-19）的现有和新兴免疫调节剂。
Expert Opin Pharmacother. 2022 Apr;23(5):623-628. doi: 10.1080/14656566.2022.2035360. Epub 2022 Feb 1.

本文引用的文献

1
EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19.EULAR 关于 COVID-19 发病机制和免疫调节治疗应用的考虑要点。
Ann Rheum Dis. 2021 Jun;80(6):698-706. doi: 10.1136/annrheumdis-2020-219724. Epub 2021 Feb 5.
2
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.巴瑞替尼联合瑞德西韦治疗住院的新冠成年患者
N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.
3
COVID-19 risk stratification algorithms based on sTREM-1 and IL-6 in emergency department.基于 sTREM-1 和 IL-6 的急诊科 COVID-19 风险分层算法。
J Allergy Clin Immunol. 2021 Jan;147(1):99-106.e4. doi: 10.1016/j.jaci.2020.10.001. Epub 2020 Oct 9.
4
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study.重症监护病房中新冠肺炎患者使用托珠单抗的多中心观察性研究。
Lancet Rheumatol. 2020 Oct;2(10):e603-e612. doi: 10.1016/S2665-9913(20)30277-0. Epub 2020 Aug 14.
5
Cytokine release syndrome in severe COVID-19.重症新型冠状病毒肺炎中的细胞因子释放综合征
Science. 2020 May 1;368(6490):473-474. doi: 10.1126/science.abb8925. Epub 2020 Apr 17.
6
How does COVID-19 kill? Uncertainty is hampering doctors' ability to choose treatments.新冠病毒是如何致人死亡的？不确定性正阻碍医生选择治疗方法的能力。
Nature. 2020 Apr;580(7803):311-312. doi: 10.1038/d41586-020-01056-7.

Tocilizumab alleviates cytokine storm with acute respiratory distress syndrome in severe SARS-CoV-2 infection in Taiwan.

作者信息

Chen Yen-Wen, Liao Hsien-Tzung

机构信息

Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

出版信息

Intern Med J. 2021 Sep;51(9):1543-1544. doi: 10.1111/imj.15335.

DOI:10.1111/imj.15335
PMID:34541767
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8653252/
Abstract
摘要